Bpifrance

Bpifrance is a financial institution dedicated to supporting companies throughout their development stages, particularly those preparing for stock market listing and seeking credit equity. The organization provides a range of financial solutions, including financing, innovation assistance, and capital investment. By integrating various entities such as OSEO and CDC Entreprises, Bpifrance aims to deliver tailored financial support that addresses the specific needs of businesses. The institution is committed to fostering innovation and helping companies transition toward sustainable growth, ensuring they are well-equipped to face future challenges.

Marion Aubry

Investment Director

Emmanuel Audouard

Director of Transverse Venture Capital Investments Division

Maufras Du Chatellier, Elyssa

Investment Director

Charlotte Corbaz

Investment Drector - Large Venture

Dahoune, Sofia

Associate

Vanessa Giraud

Director of Environmental Impact Funds

Gwenaël Hamon

Investment Director

Laurent Higueret

Senior Investment Director, Healthcare and Life Sciences - Large Venture Fund

Jacq, Véronique

Head of Digital Venture team

So-Yeon Koo

Senior Investment Manager

Eric Lefebvre

Director

Legardeur, Arnaud

Investment Director

Serge Mesguich

Director of FIT

Louis Molis

Investment Director

Adrien Neel

Investment Director

Gilles Schang

Deputy Managing Director

Past deals in Grant

Shortcut

Grant in 2022
Shortcut supports CGPs and enables automation of emailing, invitations and customer communications.

Osivax

Grant in 2022
​Osivax is a developer of immunotherapy vaccines intended to facilitate the treatment of infectious diseases. The company's vaccines expedite the uptake into dendritic cells and increase the immunogenicity of the natural protein to trigger a more effective immune response, including an unprecedented CD8 T cell activation, enabling medical practitioners to treat patients with cancer as well as influenza, malaria and other infectious diseases effectively.

Ribonexus

Grant in 2022
Ribonexus is a biotech specializing in the development of new therapies to combat cancer disease. Ribonexus, whose research and development programs are focused on the treatment of melanoma, is developing a pipeline of molecules that target the eukaryotic translation Initiation Factor-4A. (eIF4A). This target is active in a wide range of solid and hematologic cancers, including melanoma, and is linked to resistance to many current treatments. Ribonexus's goal is to deliver drugs that restore sensitivity to current targeted therapies in cancer patients who have become resistant to them.

SeaBeLife

Grant in 2022
SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

Susu

Grant in 2022
Susu is a dynamic and innovative company that offers a wide range of health services for families in the African diaspora. Susu provides a complete offer on Preventive care, Medical treatments, Management of chronic diseases, and Authentic drugs.

Pherecydes Pharma

Grant in 2022
Pherecydes Pharma operator of an innovative biotechnologies company created to develop personalized phage therapy to treat bacterial infections. The company develops bacteriophages against infections and launched multicenter European phage therapy trial to evaluate phage therapy on infected burn wounds, recognize bacterial target attached to its outer membrane, inject genetic material and reproduce in the host to make new phages that get out and repeat the same cycle, enabling doctors to detect and treat people and their environment against a large range of biothreat agents, including multi-resistant, emergent or previously uncharacterized bacteria.

Fysali

Grant in 2021
Fysali breaks the taboo by providing remote, non-invasive bladder monitoring. They offer superior clinical accuracy, an exceptional patient experience, and a lower cost of care. They offer remote and noninvasive bladder monitoring services.

Echoliv

Grant in 2021
Echoliv designs artificial intelligence solutions for abdominal ultrasound. They develop software to assist radiologists and hepatologists. The Ultraliv solution from Echoliv assists radiologists and hepatologists in early-stage ultrasound screening for the most common type of liver cancer, hepatocellular carcinoma (or HCC). The algorithm can detect nodules other than those identified by practitioners.

Luos

Grant in 2021
The world’s first open source devtool that makes hardware as agile as software

Adeunis

Grant in 2021
Adeunis specializes in the design, manufacturing and marketing of connected objects and Internet of Things (IoT) and machine-to-machine (M2M) based radio frequency transmission solutions for use in sectors including smart building, remote energy data management, industrial optimization, connected agriculture, transport, infrastructure, sport, services, etc. Also, the group designs and develops customized radio solutions tailored to the specific needs of customers. The group's activity is organized around 3 families of products: long-range radiofrequency transmission modules; ready-to-use wireless transmission systems: radio modems, radio frame transmitters and receivers, wireless communication gateways, telemetry systems, data retrieval systems, radio temperature transmitters, remote controls, etc. ; wireless communication systems: audio conferencing systems and portable radio terminals for secure and confidential communications in noisy or harsh environments, sold under Vokkero brand.
C12 Quantum Electronics is a company based in Paris, Ile-de-France, France, founded in 2019 by Pierre and Matthieu Desjardins. The company focuses on developing reliable quantum processors utilizing carbon nanotubes, which significantly reduce error rates. This technology positions C12 Quantum Electronics as a strong candidate for noisy intermediate-scale quantum applications. In addition to building quantum computers, the company also engages in developing and accelerating experiments related to information processing systems, allowing industrial clients to leverage intermediate-scale quantum applications for enhanced computing capabilities.

Biophytis

Grant in 2021
Biophytis SA is a clinical-stage biotechnology company based in Paris, France, dedicated to developing therapeutics that aim to slow degenerative processes linked to aging and enhance functional outcomes for patients with age-related diseases. The company focuses on activating key biological resilience pathways to mitigate the effects of various biological and environmental stresses that contribute to these conditions. Biophytis has two primary drug candidates: Sarconeos (BIO101), an orally administered small molecule being developed for neuromuscular diseases such as sarcopenia and Duchenne muscular dystrophy, and Macuneos (BIO201), also an orally administered small molecule targeting retinal diseases like dry age-related macular degeneration and Stargardt disease. The company has established a collaboration agreement with AFM-Telethon for the development of Sarconeos. Founded in 2006, Biophytis aims to become a leader in aging science by providing innovative therapies to address the needs of patients with limited treatment options.

OncoDiag

Grant in 2021
OncoDiag is a French biotechnology company based in Normandy at one hour from Paris and Rouen cities. The company is focused on developing of non-invasive diagnostic tests for early detection of cancers. Its lead product the Urotest (CE-IVD) is a urine test for diagnosis and surveillance of bladder cancer. The company's pipeline also includes the Colodiag in development for early detection of colorectal cancer.

Luos

Grant in 2021
The world’s first open source devtool that makes hardware as agile as software

Fysali

Grant in 2021
Fysali breaks the taboo by providing remote, non-invasive bladder monitoring. They offer superior clinical accuracy, an exceptional patient experience, and a lower cost of care. They offer remote and noninvasive bladder monitoring services.
OSE Immunotherapeutics is a biotechnology company led by immunologists focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology, auto-immune diseases, and transplantation. OSE Immunotherapeutics SA is a biotechnology business that focuses on the development of immunotherapies for immune activation and modulation in immuno-oncology and autoimmune illnesses. Tedopi, OSE-172, OSE-703, FR104, and OSE-127 are among the company's products.

Bybr

Grant in 2020
Everyday we are surrounded by local commerce and brands, and Bybr cares about connecting people to their choice and desire. Bybr brings our favorite commerce and brands online, and connecting them with customers in a personal way. Bybr opens up local opportunities for experience and connections. We provide direct access to official channels, help unify all commercial touchpoints, and allow creation of personal offerings. We develop smart technologies to meet the customers different needs, and our universal scanner is able to grab all sorts of signs: logos, barcodes, QR codes... Our 1Scan to connect solution lets customers interact with a brand or business in a simple and seamless manner. As a result, Bybr evolves the way local commerce and brands can meet customer expectations.

Multiwave Imaging

Grant in 2020
Multiwave Imaging is a leading company specializing in the design of metamaterial antennas for Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) systems. Established in March 2015 and headquartered in Geneva, Switzerland, with a research and development facility in France, Multiwave focuses on developing innovative medical imaging devices. The company aims to enhance imaging quality in MRI, ultimately aiding in the treatment of neurological conditions. In addition to its core imaging technologies, Multiwave employs advanced quantitative portfolio analysis and sensor technologies to support retailers in their purchasing strategies, thereby maximizing profits. Through these initiatives, Multiwave Imaging seeks to advance the field of medical imaging while addressing critical healthcare needs.

Osivax

Grant in 2020
​Osivax is a developer of immunotherapy vaccines intended to facilitate the treatment of infectious diseases. The company's vaccines expedite the uptake into dendritic cells and increase the immunogenicity of the natural protein to trigger a more effective immune response, including an unprecedented CD8 T cell activation, enabling medical practitioners to treat patients with cancer as well as influenza, malaria and other infectious diseases effectively.

Xenothera

Grant in 2020
Xenothera is a biotechnology company focused on developing advanced immunological treatments through its innovative xenotherapy platform. The company specializes in creating hyperimmune polyclonal sera, which enhances passive immunotherapy for various medical applications, including immunomodulation and infectious diseases. Leveraging its expertise in animal genetics and immunology, Xenothera streamlines the development process by controlling all aspects, from the selection of immunogens to the purification of immunoglobulins. This comprehensive approach allows for accelerated market authorization, positioning Xenothera as a leader in transforming immunotherapeutic solutions for the medical community.

Quantum Surgical

Grant in 2020
Quantum Surgical mission is to democratize minimally invasive liver cancer treatment

Multiwave Imaging

Grant in 2020
Multiwave Imaging is a leading company specializing in the design of metamaterial antennas for Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) systems. Established in March 2015 and headquartered in Geneva, Switzerland, with a research and development facility in France, Multiwave focuses on developing innovative medical imaging devices. The company aims to enhance imaging quality in MRI, ultimately aiding in the treatment of neurological conditions. In addition to its core imaging technologies, Multiwave employs advanced quantitative portfolio analysis and sensor technologies to support retailers in their purchasing strategies, thereby maximizing profits. Through these initiatives, Multiwave Imaging seeks to advance the field of medical imaging while addressing critical healthcare needs.

Vulkam

Grant in 2020
Vulkam is an innovative microtechnology start up from the french research laboratories.

TreeFrog Therapeutics

Grant in 2019
TreeFrog Therapeutics is a developer of stem cells intended to secure cell production and quality, fasten clinical development and facilitate market access. The company's offerings include a proprietary technology platform that provides an end to end 3D scalable solution that will dramatically reduce treatment costs, enabling patients to access the medical revolution of cell therapies by overcoming current critical manufacturing issues.

ImCheck Therapeutics

Grant in 2019
ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours.

Skipper NDT

Grant in 2019
SKIPPER NDT contacless magnetic technology enables pipeline operators to optimise their maintenance costs while increasing the safety standards of their buried networks. Our UAV based pipeline mapping service enables a centimetric precision while ensuring access to remote locations.

PECULIUM

Grant in 2019
Since 2017, Peculium has strived to bring advanced wealth management services to the world of digital assets.

TreeFrog Therapeutics

Grant in 2019
TreeFrog Therapeutics is a developer of stem cells intended to secure cell production and quality, fasten clinical development and facilitate market access. The company's offerings include a proprietary technology platform that provides an end to end 3D scalable solution that will dramatically reduce treatment costs, enabling patients to access the medical revolution of cell therapies by overcoming current critical manufacturing issues.

Alkion BioInnovations

Grant in 2019
Alkion BioInnovations was created in March 2017 in order to develop disruptive cannabinoid & pharmaceutical API production using large scale plant tissue production. The team works also on a new sugar replacement: a novel plant-based high intensive protein sweetener. The company won many R&D grants: I-lab, I-Nov, Plan de Relance & EIC Phase I; and other prize: La Fabrique Aviva, Netva, Wilco, IPA4SME...

Ascendance

Grant in 2019
Founded in 2018 by four ex-Airbus engineers: Jean-Christophe Lambert, Thibault Baldivia, Clément Dinel and Benoît Ferran, Ascendance is an industrial start-up with a mission to decarbonise aviation. Based in the heart of Toulouse, the European capital of aviation, it has developed and markets two products: an innovative hybrid-electric propulsion system ‘Sterna’, and a hybrid-electic vertical take-off and landing (VTOL) aircraft powered by Sterna technology, ‘Atea’.

Capte

Grant in 2018
Capte develops, produces and integrates smart IOT solutions for transportation, marine, production and other industries. We accelerate transition of fleets to green energies.

DNA Script

Grant in 2018
DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

DNA Script

Grant in 2018
DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

Eversend

Grant in 2017
Eversend also provides multi-currency wallets and currency exchange and plans to offer personal loans, savings, group savings, merchant payments and investments in the future. Eversend will use the funds for product development, user acquisition, and regulatory compliance, while it also intends to expand its offering to Nigeria, Francophone Africa, and Europe. Some of the funds will remain in company accounts as working capital to beef up Eversend’s netting off reserves.
OSE Immunotherapeutics is a biotechnology company led by immunologists focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology, auto-immune diseases, and transplantation. OSE Immunotherapeutics SA is a biotechnology business that focuses on the development of immunotherapies for immune activation and modulation in immuno-oncology and autoimmune illnesses. Tedopi, OSE-172, OSE-703, FR104, and OSE-127 are among the company's products.

Internest

Grant in 2017
Internest is a developer of a precise positioning system designed for rotating winged vehicles. The company's system utilizes a local landing system which is an embedded system with firmware and hardware to provide robust and accurate positioning information for all visibility, weather and environment, enabling security companies, military and maritime companies to assist drones and helicopters in their critical operations to improve flight safety.

Internest

Grant in 2017
Internest is a developer of a precise positioning system designed for rotating winged vehicles. The company's system utilizes a local landing system which is an embedded system with firmware and hardware to provide robust and accurate positioning information for all visibility, weather and environment, enabling security companies, military and maritime companies to assist drones and helicopters in their critical operations to improve flight safety.

VeriCampus

Grant in 2017
VeriCampus enables College/Universities to provide personalized student support at scale, utilizing Artificial Intelligence. We develop AI-powered ‘Campus Assistant’ Chatbots that take on the character and knowledgebase of the institution, helping students successfully navigate through college.

Mash&Co

Grant in 2017
Developer of an interactive animation-based application intended to offer instruments to let kids understand valuable things. The company's application stimulates creativity and logic, and offers a range of kid games, enabling kids to interact, coordinate and recognize through cartoon series, interactive cartoons, mini-games, and episodes.

Conscious Labs

Grant in 2016
Conscious Labs specializes in developing brain-computer interface (BCI) technology that allows for the collection of research-grade EEG data in real-world settings. The company creates advanced head-wearable devices designed to integrate seamlessly into headphones, earbuds, and VR and AR headsets. This technology enables electronics manufacturers and startups to embed BCI capabilities into their products, facilitating out-of-lab research and enhancing user experiences. Additionally, Conscious Labs offers expertise in sensor development and provides an innovative ionic polymer suitable for biosensors in wearable devices, thereby advancing the capabilities of biosensing technologies.

Seamless Waves

Grant in 2016
Seamless Waves is a company specialized in the design and implementation of reconfigurable RF transceivers. These transceivers are capable of sweeping the frequency spectrum, identifying the least occupied frequency band and then establishing a communication using the wireless standard adapted to this band. Thanks to their highly efficient RF Analog-to-Digital converters, these transceivers achieve a very low power consumption that is well suited for portable devices. Seamless Waves is also a provider of silicon-proven Analog/RF Physical IPs and their virtual component models that can be used for early system integration.

Alkion BioInnovations

Grant in 2016
Alkion BioInnovations was created in March 2017 in order to develop disruptive cannabinoid & pharmaceutical API production using large scale plant tissue production. The team works also on a new sugar replacement: a novel plant-based high intensive protein sweetener. The company won many R&D grants: I-lab, I-Nov, Plan de Relance & EIC Phase I; and other prize: La Fabrique Aviva, Netva, Wilco, IPA4SME...
Open Mind Innovation, team of 19 (9Ph.D.). Developps neurotraining services and content + numerous neurotech mandatory assests as normative (multimodal) database, VR stimuli, neurotraining content, reel time multimodal signal processing (TimeFlux) anonymized repository (Quetzal) platforms, IP, trade secrets and open science publications related to neurotechnology.

Polywed

Grant in 2016
Polywed is a Healthcare IT company developing the data-driven technology that increases in vitro fertilization (IVF) success rates. Today average IVF live birth rate is about 30%. BioChron technology doubles the efficiency of the treatment up to 60%.

Connected Cycle

Grant in 2015
Connected Cycle specializes in geolocation solutions designed for bicycles and industrial assets. The company provides a comprehensive portfolio that includes sensors and a fleet management platform, which enables real-time monitoring and tracking of both bikes and containers. By offering metrics and reports on service usage and availability, Connected Cycle ensures that clients can effectively manage their outdoor tracking needs in a cost-effective manner.

Ledger

Grant in 2015
Ledger develops security and infrastructure solutions for cryptocurrencies as well as blockchain applications for individuals and companies, by leveraging a distinctive, proprietary technology. Launched in 2014, Ledger has designed an acclaimed line of hardware security devices quickly placing the company as a global leader on the market with 1,000,000 units sold in more than 165 countries. For enterprises and corporations, Ledger introduced the Vault: a fully managed SaaS solution addressing the need to safeguard a very large amount of multiple cryptocurrencies while mitigating both IT and physical assault threats. The company is also active on the industrial IoT market, leveraging its secure hardware technology to interface sensors and machines to smart contracts or blockchain based assets. Ledger is headquartered in Paris, has a production facility in Vierzon (France) and offices in San Francisco.

Q°emotion

Grant in 2015
Q°emotion is an emotional and semantic solution for analysing the opinions of your customers and employees. Their SaaS platform detects the emotions and sensations felt to provide insights and improve experience.

Antabio

Grant in 2015
Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. It develops stand-alone inhibitors of bacterial metalloenzymes that can be combined with various antibiotics to restore their activity against the most critical pathogens. The company's novel inhibitor of bacterial Metallo ß-lactamases (“MBLs”) which will be combined with a carbapenem to fill an important gap in the treatment of drug-resistant infections. They develop a novel, safe and efficacious inhibitor of bacterial Metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections. Antabio received a Wellcome Trust Seeding Drug Discovery Award. The company was founded in 2009 and is headquartered in Labege, France.

Magnisense

Grant in 2015
Magnisense conçoit, développe et commercialise des tests de diagnostic d'urgence pour les maladies cardio-vasculaires à partir de sa technologie MIAtek® et de son instrument de diagnostic propriétaires

Theravectys

Grant in 2015
Theravectys is a development-stage biotechnology company with a novel vaccine platform that can be applied to the treatment and prevention of a broad range of infectious diseases, cancers, and other diseases and conditions. Their first clinical studies will be in HIV/AIDS, using their lead product, a therapeutic vaccine, which has shown promising efficacy and safety in non-human primates.

Connected Cycle

Grant in 2014
Connected Cycle specializes in geolocation solutions designed for bicycles and industrial assets. The company provides a comprehensive portfolio that includes sensors and a fleet management platform, which enables real-time monitoring and tracking of both bikes and containers. By offering metrics and reports on service usage and availability, Connected Cycle ensures that clients can effectively manage their outdoor tracking needs in a cost-effective manner.

Antabio

Grant in 2013
Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. It develops stand-alone inhibitors of bacterial metalloenzymes that can be combined with various antibiotics to restore their activity against the most critical pathogens. The company's novel inhibitor of bacterial Metallo ß-lactamases (“MBLs”) which will be combined with a carbapenem to fill an important gap in the treatment of drug-resistant infections. They develop a novel, safe and efficacious inhibitor of bacterial Metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections. Antabio received a Wellcome Trust Seeding Drug Discovery Award. The company was founded in 2009 and is headquartered in Labege, France.

Nanobiotix

Grant in 2013
Nanobiotix SA develops nanomedicine programs for the treatment of cancer. The company provides NanoXray that offers a solution for cancer therapy based on a technology that is designed to allow destruction of cancer cells by inert particles. Its products include magnetic particles and laser activated nanoparticles for the treatment and diagnostic of cancer.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.